Skip to main content
LISATA THERAPEUTICS, INC. logo

LISATA THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · LSTA ISIN · US1280583022 LEI · 5493002287F62M3EGQ04 US Manufacturing
Open in API
Filings indexed 1,093 across all filing types
Latest filing 2017-01-06 Regulatory Filings
Country US United States of America
Listing US LSTA

About LISATA THERAPEUTICS, INC.

https://www.lisata.com/

Lisata Therapeutics is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for advanced solid tumors and other major diseases. The company's core technology is the proprietary CendR Platform®, designed to enhance the targeted, tissue-penetrating delivery of anti-cancer drugs to solid tumors. The platform also aims to target non-cancerous, immunosuppressive cells within the tumor microenvironment, seeking to improve the efficacy of a patient's immune system and immunotherapies in fighting cancer.

Recent filings

Filing Released Lang Actions
8-K 01.06.17
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated January 6, 2017, for Caladrius Biosciences, Inc. It references a press release related to a previously announced private placement in September 2016. The document is short (2286 characters) and primarily serves to furnish a press release as an exhibit. There are no financial statements or detailed financial data included. The content is an announcement of an event (private placement update) rather than a full financial report or detailed filing. According to the rules, such filings that announce events or furnish press releases without substantive financial data are best classified as Regulatory Filings (RNS).
2017-01-06 English
S-8 01.06.17
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans, such as equity compensation plans. It includes details about the number of shares registered, the equity plan, and references to prior filings. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, it fits best under the category of Regulatory Filings (RNS). The document length and content confirm it is not a brief announcement or a report publication announcement but a full registration statement filing.
2017-01-06 English
8-K 12.30.16
Board/Management Information Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, specifically reporting the resignation of a director, Dr. Andrew Pecora, from the company's board. The key section is Item 5.02, which relates to changes in directors or principal officers. There is no financial data or report attached, and the document is focused on management changes. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is short and it is not an announcement of a report publication or a certification, so it is not RPA or RNS. Therefore, the correct classification is MANG with high confidence.
2016-12-30 English
Regulatory Filings 2016
Regulatory Filings
2016-12-20 English
PROSUPP424B3DECEMBER2016
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(3) related to the resale of common stock by selling stockholders. It includes detailed information about the offering, risk factors, use of proceeds, selling stockholders, and plan of distribution. The document is not a financial report, earnings release, or management discussion. It is a legal and regulatory filing related to securities offering and resale, specifically a prospectus supplement. This type of document fits the category of Capital/Financing Update (CAP), as it provides updates on securities offerings and related capital structure changes.
2016-12-19 English
Regulatory Filings 2016
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC requesting acceleration of the effective date of a Registration Statement on Form S-3. It is a formal correspondence related to a securities registration process, not a financial report or detailed filing. The document length is short (1723 characters) and it does not contain financial data or report content. It is an announcement/request related to a regulatory filing, specifically a request for acceleration of a registration statement effectiveness. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2016-12-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.